You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Fosinopril Sodium And Hydrochlorothiazide patents expire, and when can generic versions of Fosinopril Sodium And Hydrochlorothiazide launch?

Fosinopril Sodium And Hydrochlorothiazide is a drug marketed by Ani Pharms, Aurobindo Pharma, Avet Lifesciences, Invagen Pharms, Mylan, Sandoz, Sun Pharm Inds Ltd, and Teva. and is included in nine NDAs.

The generic ingredient in FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE is fosinopril sodium; hydrochlorothiazide. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fosinopril sodium; hydrochlorothiazide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Fosinopril Sodium And Hydrochlorothiazide

A generic version of FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE was approved as fosinopril sodium; hydrochlorothiazide by SANDOZ on September 28th, 2005.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE?
  • What are the global sales for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE?
  • What is Average Wholesale Price for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE?
Summary for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE
Drug patent expirations by year for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE
Recent Clinical Trials for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ranbaxy Laboratories LimitedN/A

See all FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE clinical trials

Pharmacology for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

US Patents and Regulatory Information for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE fosinopril sodium; hydrochlorothiazide TABLET;ORAL 076608-001 Dec 3, 2004 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Teva FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE fosinopril sodium; hydrochlorothiazide TABLET;ORAL 076945-002 Jul 5, 2006 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Avet Lifesciences FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE fosinopril sodium; hydrochlorothiazide TABLET;ORAL 079025-001 Sep 17, 2010 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Ani Pharms FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE fosinopril sodium; hydrochlorothiazide TABLET;ORAL 077144-002 Aug 16, 2005 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Mylan FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE fosinopril sodium; hydrochlorothiazide TABLET;ORAL 077705-002 Aug 14, 2006 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Avet Lifesciences FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE fosinopril sodium; hydrochlorothiazide TABLET;ORAL 079025-002 Sep 17, 2010 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Sun Pharm Inds Ltd FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE fosinopril sodium; hydrochlorothiazide TABLET;ORAL 076739-002 Dec 17, 2004 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.